different drug, different mechanism of action, different protein target (membrane-bound rather than soluble), and different indication
really quite irrelevant to efti, only downside is imm will miss out on some future milestone payments but the company is funded through 2022 so not a huge deal
im sure the market will overreact though
Ann: Ulcerative Colitis Phase II Study of GSK2831781 Discontinued, page-7
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
26.0¢ |
Change
0.010(4.00%) |
Mkt cap ! $379.7M | |||
| Open | High | Low | Value | Volume |
| 25.0¢ | 26.5¢ | 24.5¢ | $1.104M | 4.311M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 94145 | 26.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 26.5¢ | 474112 | 7 |
View Market Depth
| Last trade - 16.10pm 17/07/2025 (20 minute delay) ? |
| IMM (ASX) Chart |